Sertindole
From Wikipedia, the free encyclopedia
| |
| Sertindole
| |
| Systematic (IUPAC) name | |
| 1-[2-[4-[5-chloro-1-(4-fluorophenyl)- indol-3-yl]-1-piperidyl]ethyl] imidazolidin-2-one | |
| Identifiers | |
| CAS number | 106516-24-9 |
| ATC code | N05AE03 |
| PubChem | 60149 |
| DrugBank | none |
| Chemical data | |
| Formula | C24H26ClFN4O |
| Mol. weight | 440.941 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | ? |
Sertindole (brand names: Serlect®, Serdolect®) is one of the newer antipsychotic medications to hit the market. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.
Sertindole promises a restricted receptor and brain site activity. Its activity appears to be specific to D2, 5-HT2 and alpha-1 adrenergic receptors and largely confined to the limbic dopamine system of the brain (without inhibiting activity in the nigrostriatal dopamine system), at least in animal in vivo and in vitro studies.
Sertindole is reported to have an anxiolytic property, to be not sedating and not to impair cognitive functions.
Sertindole was withdrawn from the market on December 2, 1998 due to concerns over the risk of cardiac arrhythmia and sudden death.
[edit] External link
- Important safety message: Serdolect (sertindole) - suspension of marketing authorisation following EC decision
